Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Molecular Profile Analysis Refines Subtypes of DLBCL

Publish date:: November 3, 2019

Key clinical point: An integrated analysis of clinical trial data has refined previously described subgroups of patients with diffuse large B-cell lymphoma (DLBCL).

Major finding: Across the cohort, 38 independent components related to transcriptomic variability were detected, with substantial heterogeneity observed among previously characterized disease subtypes.

Study details: An integrated cohort analysis of 223 patients with de novo CD20+ DLBCL.

Disclosures: The study was funded by the Institut National du Cancer (France). The authors reported financial affiliations with Abbvie, Amgen, BMS, Celgene, Gilead, Pfizer, Roche, and several others.

Citation:

Dubois S et al. EBioMedicine. 2019 Oct 21. doi: 10.1016/j.ebiom.2019.09.034.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,